IMMUNOME INC
IMNMNASDAQTrading Snapshot
- Day Range
- $18.11 – $19.27
- 52-Week Range
- $14.64 – $30.06
- Volume (shares)
- 59,010
- Avg Volume (shares)
- —
- Shares Outstanding
- 118.0M
- Next Earnings
- 2026-11-16
Fundamentals Snapshot
- Annual Revenue
- $7M
- Last Q Revenue
- —
- P/E Ratio
- -7.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-2.25
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +39.3%
IMMUNOME INC
IMNM
StockOtter · stockotter.spaceAbout IMMUNOME INC
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
News unavailable.